Drug Profile
HG 146
Alternative Names: HG-146Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator HitGen
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Multiple myeloma; Solid tumours
Most Recent Events
- 28 Jun 2023 HitGen terminates a phase I trial in Multiple-myeloma (Second-line therapy or greater) in China (PO, Capsule) due to company decision (NCT03710915)
- 12 Sep 2022 HG 146 is still in phase I trials in Multiple-myeloma (Second-line therapy) in China (PO, Capsule) (HitGen pipeline, September 2022) (NCT03710915)
- 01 Mar 2022 Phase-I clinical trials in Lymphoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT04977167)